BMC Cancer · 2023 · 20 citations · 36 references
MedicineBioinformaticsOncologyGene ExpressionMolecular OncologyTumor MicroenvironmentCancer BiomarkersCancer TranscriptomicsImmuno-oncology BiomarkersPancreatic CancerTumor Immune MicroenvironmentTumor ImmunopathologyCancer-associated ImmunosuppressionImmune Checkpoint BiomarkersImmune Infiltration BiomarkersImmunosuppressive MicroenvironmentMicroarray AnalysisS100 Protein ExpressionS100 ProteinsTumor Microenvironment Biomarkers
BACKGROUND: Immunosuppression is a significant factor contributing to the poor prognosis of cancer. S100P, a member of the S100 protein family, has been implicated in various cancers. However, its role in the tumor microenvironment (TME) of pancreatic cancer remains unclear. This study aimed to investigate the potential impact of S100P on TME characteristics in patients with pancreatic cancer. METHODS: Multiple data (including microarray, RNA-Seq, and scRNA-Seq) were obtained from public databases. The expression pattern of S100P was comprehensively evaluated in RNA-Seq data and validated in four different microarray datasets. Prognostic value was assessed through Kaplan-Meier plotter and Cox regression analyses. Immune infiltration levels were determined using the ESTIMATE and ssGSEA algorithms and validated at the single-cell level. Spearman correlation test was used to examine the correlation between S100P expression and immune checkpoint genes, and tumor mutation burden (TMB). DNA methylation analysis was performed to investigate the change in mRNA expression. Reverse transcription PCR (RT-PCR) and immunohistochemical (IHC) were utilized to validate the expression using five cell lines and 60 pancreatic cancer tissues. RESULTS: This study found that S100P was differentially expressed in pancreatic cancer and was associated with poor prognosis (P < 0.05). Notably, S100P exhibited a significant negative-correlation with immune cell infiltration, particularly CD8 + T cells. Furthermore, a close association between S100P and immunotherapy was observed, as it strongly correlated with TMB and the expression levels of TIGIT, HAVCR2, CTLA4, and BTLA (P < 0.05). Intriguingly, higher S100P expression demonstrated a negative correlation with methylation levels (cg14323984, cg27027375, cg14900031, cg14140379, cg25083732, cg07210669, cg26233331, and cg22266967), which were associated with CD8 + T cells. In vitro RT-PCR validated upregulated S100P expression across all five pancreatic cancer cell lines, and IHC confirmed high S100P levels in pancreatic cancer tissues (P < 0.05). CONCLUSION: These findings suggest that S100P could serve as a promising biomarker for immunosuppressive microenvironment, which may provide a novel therapeutic way for pancreatic cancer.
36
Rebecca L. Siegel, Kimberly D. Miller, Hannah E. Fuchs et al. · CA A Cancer Journal for Clinicians · 2022 · 18.2K citations · Full text
Inferring tumour purity and stromal and immune cell admixture from expression data
Kosuke Yoshihara, Maria Shahmoradgoli, Emmanuel Martínez et al. · Nature Communications · 2013 · 10.7K citations · Full text
GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses
Zefang Tang, Chenwei Li, Chenwei Li et al. · Nucleic Acids Research · 2017 · 10.6K citations · Full text
The Immune Landscape of Cancer
Vésteinn Thórsson, David L. Gibbs, Scott D. Brown et al. · Immunity · 2018 · 6.2K citations · Full text
Medicine, Immunology, Oncology +17
Maftools: efficient and comprehensive analysis of somatic variants in cancer
Anand Mayakonda, De‐Chen Lin, Yassen Assenov et al. · Genome Research · 2018 · 5.4K citations · Full text